Part B: Immunological Therapies for Lung Cancer

Yucel A.

LUNG CANCER: CLINICAL AND SURGICAL SPECIFICATIONS, ss.455-465, 2013 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Basım Tarihi: 2013
  • Dergi Adı: LUNG CANCER: CLINICAL AND SURGICAL SPECIFICATIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
  • Sayfa Sayıları: ss.455-465
  • Anahtar Kelimeler: Lung cancer, immunotherapy, vaccine, antibody-based treatment, cetuximab, bevacizumab, panitumumab, matuzumab, pertuzumab, transtuzumab, erlotinin, paclitaxel, carboplatin, gemtuzumab, GVAX, MUC1, MAGE-A3, TG4010, GROWTH-FACTOR RECEPTOR, SMALL CELL-CARCINOMA, PHASE-II TRIAL, TUMOR-NECROSIS-FACTOR, MONOCLONAL-ANTIBODIES, IMMUNOTHERAPY, VACCINATION, INTERLEUKIN-2, CHEMOTHERAPY, COMBINATION
  • Gazi Üniversitesi Adresli: Evet

Özet

Lung cancer is a disease with very high morbidity and mortality rate. In spite of aggressive treatment modalities, the long-term survival is very low, and these treatments have many toxic adverse effects. Immunological therapies or briefly "immunotherapy" is a promising new therapeutic modality for lung cancer; it can be in the form of active immunization (cancer vaccines), passive immunization (adoptive cell therapy or antibody-based treatment) or immunostimulation.